Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Receives $75.71 Average Price Target from Brokerages

Key Points

• Structure Therapeutics Inc. has an average analyst rating of "Buy", with eight analysts recommending buying and one issuing a strong buy, suggesting positive sentiment in the market.
• The average 1-year price target for the stock is approximately $75.71, indicating potential for significant growth from its current price.
• Institutional investors hold 91.78% of Structure Therapeutics shares, reflecting strong institutional confidence in the company's future performance.

Shares of Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR - Get Free Report) have been assigned a consensus recommendation of "Buy" from the nine research firms that are currently covering the company, MarketBeat.com reports. Eight equities research analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $75.7143.

Several equities analysts have weighed in on GPCR shares. JMP Securities dropped their target price on shares of Structure Therapeutics from $89.00 to $87.00 and set a "market outperform" rating for the company in a report on Thursday, August 7th. HC Wainwright reduced their target price on shares of Structure Therapeutics from $75.00 to $60.00 and set a "buy" rating on the stock in a report on Thursday, August 7th. Cantor Fitzgerald restated an "overweight" rating and issued a $65.00 target price on shares of Structure Therapeutics in a report on Monday, June 23rd. Guggenheim reduced their target price on shares of Structure Therapeutics from $92.00 to $90.00 and set a "buy" rating on the stock in a report on Thursday, August 7th. Finally, Lifesci Capital upgraded shares of Structure Therapeutics to a "strong-buy" rating in a report on Monday, September 8th.

Institutional Trading of Structure Therapeutics

A number of institutional investors have recently modified their holdings of the company. Vestal Point Capital LP boosted its holdings in Structure Therapeutics by 3.7% in the first quarter. Vestal Point Capital LP now owns 1,788,990 shares of the company's stock valued at $30,967,000 after purchasing an additional 63,990 shares during the last quarter. Ameriprise Financial Inc. boosted its holdings in Structure Therapeutics by 7.2% in the second quarter. Ameriprise Financial Inc. now owns 1,588,198 shares of the company's stock worth $32,939,000 after purchasing an additional 106,389 shares during the period. Orbimed Advisors LLC boosted its holdings in Structure Therapeutics by 49.5% in the second quarter. Orbimed Advisors LLC now owns 1,199,300 shares of the company's stock worth $24,873,000 after purchasing an additional 397,272 shares during the period. Readystate Asset Management LP boosted its position in Structure Therapeutics by 129.9% during the 1st quarter. Readystate Asset Management LP now owns 481,241 shares of the company's stock valued at $8,330,000 after purchasing an additional 271,899 shares during the period. Finally, Pacific Heights Asset Management LLC acquired a new position in Structure Therapeutics during the 2nd quarter valued at approximately $9,540,000. Hedge funds and other institutional investors own 91.78% of the company's stock.

Structure Therapeutics Stock Performance

NASDAQ:GPCR traded up $0.35 during mid-day trading on Tuesday, hitting $23.58. 970,042 shares of the company's stock traded hands, compared to its average volume of 1,104,251. The firm's 50 day simple moving average is $19.22 and its 200 day simple moving average is $20.67. Structure Therapeutics has a 1 year low of $13.22 and a 1 year high of $45.37. The company has a market cap of $1.36 billion, a PE ratio of -22.46 and a beta of -1.88.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last posted its earnings results on Wednesday, August 6th. The company reported ($0.36) earnings per share for the quarter, missing the consensus estimate of ($0.28) by ($0.08). On average, research analysts expect that Structure Therapeutics will post -0.82 earnings per share for the current fiscal year.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.